CTLA4 and neoplasm: In the metastatic breast cancer model, the combination of LSAM-DTX + anti-CTLA-4 resulted in significant decrease in TV and thoracic metastasis and increased T cells, NK cells, and NKT cells in the tumor site and peripheral blood.